Visus Company Profile
What is the competitive landscape for VISUS
VISUS has one approved drug.
There are two US patents protecting VISUS drugs.
Summary for Visus
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Visus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visus | YUVEZZI | brimonidine tartrate; carbachol | SOLUTION/DROPS;OPHTHALMIC | 220142-001 | Jan 28, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Visus | YUVEZZI | brimonidine tartrate; carbachol | SOLUTION/DROPS;OPHTHALMIC | 220142-001 | Jan 28, 2026 | RX | Yes | Yes | 8,455,494 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Visus | YUVEZZI | brimonidine tartrate; carbachol | SOLUTION/DROPS;OPHTHALMIC | 220142-001 | Jan 28, 2026 | RX | Yes | Yes | 12,268,662 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Visus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2023086878 | ⤷ Start Trial |
| European Patent Office | 4429652 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2010135731 | ⤷ Start Trial |
| Taiwan | 202333662 | ⤷ Start Trial |
| China | 118541148 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Visus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1631293 | 201440029 | Slovenia | ⤷ Start Trial | PRODUCT NAME: BRIMONIDINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; NATIONAL AUTHORISATION NUMBER: EU/1/13/904/001-003; DATE OF NATIONAL AUTHORISATION: 20140221; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 1631293 | 2014/041 | Ireland | ⤷ Start Trial | PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221 |
| 1631293 | 14C0056 | France | ⤷ Start Trial | PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 1631293 | 92462 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225 |
| 1631293 | 2014C/042 | Belgium | ⤷ Start Trial | PRODUCT NAME: MIRVASO (BRIMONIDINE) EN FARMACEUTISCHE ZOUTEN DAARVAN VOOR GEBRUIK ALS MEDICIJN VOOR HET BEHANDELEN VAN ROSACEA GEINDUCEERDE ROODHEID; AUTHORISATION NUMBER AND DATE: EU/1/13/904 20140221 |
| 1631293 | 300683 | Netherlands | ⤷ Start Trial | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| 1631293 | C300683 | Netherlands | ⤷ Start Trial | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
